Alfacalcidol-d7
Alfacalcidol-d7 is the deuterium labeled Alfacalcidol. Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis[1][2][3][4].
Product Specifications
Product Name Alternative
1-hydroxycholecalciferol-d7; 1.alpha.-Hydroxyvitamin D3-d7
UNSPSC
12352211
Target
Isotope-Labeled Compounds; VD/VDR
Type
Isotope-Labeled Compounds
Related Pathways
Others; Vitamin D Related/Nuclear Receptor
Field of Research
Metabolic Disease
Solubility
10 mM in DMSO
Smiles
C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](CCCC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C)CCC/2)[H])O)O
Molecular Formula
C27H37D7O2
Molecular Weight
407.68
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Galeşanu C, et al. [Postmenopausal osteoporosis. Digital Rx radiogrammetry in the diagnosis and follow-up of treatment with alfacalcidol]. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110 (4) :833-41.|[3]Nuijten M, et al. Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK. Clin Drug Investig. 2010;30 (8) :545-57.|[4]Shiraishi A, et al. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int. 1999 Oct;65 (4) :311-6.|[5]Nagaoka H, et al. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J Orthop Res. 2014 Aug;32 (8) :1030-6.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
